Logo image of PRPO

PRECIPIO INC (PRPO) Stock Fundamental Analysis

USA - NASDAQ:PRPO - US74019L6020 - Common Stock

20.78 USD
-0.07 (-0.34%)
Last: 10/3/2025, 8:00:01 PM
Fundamental Rating

2

Overall PRPO gets a fundamental rating of 2 out of 10. We evaluated PRPO against 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PRPO have multiple concerns. PRPO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRPO had negative earnings in the past year.
PRPO had a positive operating cash flow in the past year.
In the past 5 years PRPO always reported negative net income.
PRPO had negative operating cash flow in 4 of the past 5 years.
PRPO Yearly Net Income VS EBIT VS OCF VS FCFPRPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

PRPO has a Return On Assets of -9.57%. This is in the lower half of the industry: PRPO underperforms 76.24% of its industry peers.
PRPO has a worse Return On Equity (-14.66%) than 64.36% of its industry peers.
Industry RankSector Rank
ROA -9.57%
ROE -14.66%
ROIC N/A
ROA(3y)-38.11%
ROA(5y)-41.96%
ROE(3y)-50.29%
ROE(5y)-56.88%
ROIC(3y)N/A
ROIC(5y)N/A
PRPO Yearly ROA, ROE, ROICPRPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 44.69%, PRPO is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
In the last couple of years the Gross Margin of PRPO has grown nicely.
PRPO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.74%
GM growth 5Y42.15%
PRPO Yearly Profit, Operating, Gross MarginsPRPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

PRPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRPO has been increased compared to 1 year ago.
Compared to 5 years ago, PRPO has more shares outstanding
PRPO has a worse debt/assets ratio than last year.
PRPO Yearly Shares OutstandingPRPO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
PRPO Yearly Total Debt VS Total AssetsPRPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

PRPO has an Altman-Z score of -3.94. This is a bad value and indicates that PRPO is not financially healthy and even has some risk of bankruptcy.
PRPO has a Altman-Z score of -3.94. This is amonst the worse of the industry: PRPO underperforms 89.11% of its industry peers.
PRPO has a debt to FCF ratio of 1.47. This is a very positive value and a sign of high solvency as it would only need 1.47 years to pay back of all of its debts.
PRPO has a better Debt to FCF ratio (1.47) than 87.13% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that PRPO is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.05, PRPO belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.47
Altman-Z -3.94
ROIC/WACCN/A
WACC8.81%
PRPO Yearly LT Debt VS Equity VS FCFPRPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

PRPO has a Current Ratio of 0.93. This is a bad value and indicates that PRPO is not financially healthy enough and could expect problems in meeting its short term obligations.
PRPO has a worse Current ratio (0.93) than 77.23% of its industry peers.
PRPO has a Quick Ratio of 0.93. This is a bad value and indicates that PRPO is not financially healthy enough and could expect problems in meeting its short term obligations.
PRPO's Quick ratio of 0.69 is on the low side compared to the rest of the industry. PRPO is outperformed by 82.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.69
PRPO Yearly Current Assets VS Current LiabilitesPRPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

PRPO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.83%, which is quite impressive.
Looking at the last year, PRPO shows a very strong growth in Revenue. The Revenue has grown by 27.03%.
The Revenue has been growing by 42.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.54%
Revenue 1Y (TTM)27.03%
Revenue growth 3Y27.94%
Revenue growth 5Y42.72%
Sales Q2Q%27.22%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRPO Yearly Revenue VS EstimatesPRPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRPO Yearly EPS VS EstimatesPRPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRPO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRPO Price Earnings VS Forward Price EarningsPRPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

PRPO's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 59.58
EV/EBITDA N/A
PRPO Per share dataPRPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECIPIO INC

NASDAQ:PRPO (10/3/2025, 8:00:01 PM)

20.78

-0.07 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-17 2025-11-17
Inst Owners5.75%
Inst Owner Change-40.71%
Ins Owners12.81%
Ins Owner Change3.01%
Market Cap33.66M
Analysts82.86
Price TargetN/A
Short Float %0.1%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF 59.58
P/OCF 36.79
P/B 2.74
P/tB 37.66
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.35
FCFY1.68%
OCF(TTM)0.56
OCFY2.72%
SpS13.11
BVpS7.59
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.57%
ROE -14.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.69%
FCFM 2.66%
ROA(3y)-38.11%
ROA(5y)-41.96%
ROE(3y)-50.29%
ROE(5y)-56.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.74%
GM growth 5Y42.15%
F-Score6
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.47
Debt/EBITDA N/A
Cap/Depr 25.53%
Cap/Sales 1.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.69
Altman-Z -3.94
F-Score6
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)15.96%
Cap/Depr(5y)23.27%
Cap/Sales(3y)1.67%
Cap/Sales(5y)3.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105.54%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.03%
Revenue growth 3Y27.94%
Revenue growth 5Y42.72%
Sales Q2Q%27.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.03%
OCF growth 3YN/A
OCF growth 5YN/A